Market Place
Sourcing Support
Exelixis To Webcast Fireside Chats At March Investor Conferences
24 Feb 2026 //
BUSINESSWIRE
Exelixis Unveils 2025 Financials, Corporate Update
10 Feb 2026 //
BUSINESSWIRE
Exelixis to Report Q4, FY 2025 Results on Feb. 10
27 Jan 2026 //
BUSINESSWIRE
Exelixis Aims To Be A Top 5 Solid Tumor Drugmaker In The US: CEO
16 Jan 2026 //
FIERCE BIOTECH
Exelixis Reports 2025 Results, Issues 2026 Guidance
11 Jan 2026 //
BUSINESSWIRE
Exelixis, Natera Partner On Zanzalintinib Phase 3 Trial
07 Jan 2026 //
BUSINESSWIRE
Exelixis To Present At J.P. Morgan 2026 Healthcare Conference
06 Jan 2026 //
BUSINESSWIRE
Exelixis To Webcast 2025 R&D Day On December 10
03 Dec 2025 //
BUSINESSWIRE
Exelixis To Webcast Fireside Chats At November Investor
06 Nov 2025 //
BUSINESS WIRE
Exelixis Unveils Q3 2025 Financials & Corporate updates
04 Nov 2025 //
BUSINESSWIRE
Exelixis To Report Q3 2025 Financial Results On November 4
21 Oct 2025 //
BUSINESSWIRE
Exelixis plans shuttering of East Coast site, 130 layoffs
29 Aug 2025 //
FIERCE BIOTECH
Exelixis Names Dana T. Aftab, Ph.D. Executive VP of R&D
29 Aug 2025 //
BUSINESSWIRE
Exelixis Plans Shuttering of East Coast site, 130 layoffs
27 Aug 2025 //
FIERCE BIOTECH
Exelixis to Webcast Chats at September Investor Conference
27 Aug 2025 //
BUSINESSWIRE
Exelixis Reveals Q2 2025 Financial Results and Corporate Update
28 Jul 2025 //
BUSINESSWIRE
Exelixis to Release Q2 2025 Financial Results on July 28, 2025
14 Jul 2025 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats at Investor Conferences
22 May 2025 //
BUSINESSWIRE
Exelixis Reports Positive STELLAR-002 Trial Results at ASCO 2025
22 May 2025 //
BUSINESSWIRE
Exelixis Announces Q1 2025 Financial Results and Corporate Update
13 May 2025 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats at Investor Conferences in May
07 May 2025 //
BUSINESSWIRE
Exelixis to Release Q1 2025 Financial Results on May 13, 2025
29 Apr 2025 //
BUSINESSWIRE
Exelixis gets FDA approval for CABOMETYX in neuroendocrine tumors
26 Mar 2025 //
BUSINESSWIRE
Exelixis to Present Preclinical Data at AACR 2025
25 Mar 2025 //
BUSINESSWIRE
Exelixis To Webcast Fireside Chats At March Investor Conferences
25 Feb 2025 //
BUSINESSWIRE
Exelixis Authorizes $500M Stock Repurchase Program
20 Feb 2025 //
BUSINESSWIRE
Exelixis Reveals Five-Year CABOMETYX-Opdivo Data At ASCO GU
15 Feb 2025 //
BUSINESSWIRE
Exelixis to Participate in Citi 2025 Virtual Leadership Summit
13 Feb 2025 //
BUSINESSWIRE
Exelixis Reports Q4 & FY 2024 Results, Corporate Update
11 Feb 2025 //
BUSINESSWIRE
Exelixis To Release Q4 & Full Year 2024 Financial Result On Feb 11
28 Jan 2025 //
BUSINESSWIRE
Exelixis`s Cabozantinib Ph 3 Study In GI Tumors Present At ASCO GI
24 Jan 2025 //
BUSINESSWIRE
Exelixis`s Zanzalintinib Phase 1b/2 Trial Data Presented At ASCO GI
24 Jan 2025 //
BUSINESSWIRE
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results
12 Jan 2025 //
BUSINESSWIRE
FDA cancels adcomm for Cabometyx in neuroendocrine tumors
10 Jan 2025 //
FIERCE PHARMA
Exelixis Shares Cabozantinib Update For Advanced Neuroendocrine
09 Jan 2025 //
BUSINESSWIRE
Exelixis to Present at 43rd Annual J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
Sairopa Achieves Research Milestones in Exelixis, $35M in Payments
17 Dec 2024 //
PR NEWSWIRE
ICER calls out drugmakers over `unsupported` price hikes
12 Dec 2024 //
REUTERS
FDA oncology to weigh Exelixis` Cabometyx in neuroendocrine tumors
30 Nov 2024 //
FIERCE PHARMA
Exelixis to Webcast Chats at December Investor Conferences
27 Nov 2024 //
BUSINESSWIRE
Exelixis Provides Update on Cabozantinib for Neuroendocrine Tumors
26 Nov 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats at November Investor Conferences
07 Nov 2024 //
BUSINESSWIRE
Exelixis Announces Q3 2024 Financial Results and Update
29 Oct 2024 //
BUSINESSWIRE
Exelixis stock rises as Cabometyx withstands patent challenge
16 Oct 2024 //
FIERCE PHARMA
Exelixis Updates On Second Patent Litigation Trial With MSN Labs
15 Oct 2024 //
BUSINESSWIRE
Exelixis To Release Q3 2024 Financial Results On October 29
15 Oct 2024 //
BUSINESSWIRE
Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan
17 Sep 2024 //
FIERCE PHARMA
Exelixis Presents CABINET Study Results At ESMO 2024
16 Sep 2024 //
BUSINESSWIRE
Exelixis Presents CONTACT-02 Results For Cabozantinib Combo At ESMO
15 Sep 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
28 Aug 2024 //
BUSINESSWIRE
Invenra Highlights Exelixis` Phase 1 Trial Of XB010 In Advanced Solid Tumors
07 Aug 2024 //
BUSINESSWIRE
FDA Accepts Exelixis` sNDA For Cabozantinib In Advanced NET
06 Aug 2024 //
BUSINESSWIRE
Exelixis Announces Second Quarter 2024 Financial Results and Corporate Update
06 Aug 2024 //
BUSINESSWIRE
Exelixis To Release Q2 2024 Results On August 6
23 Jul 2024 //
BUSINESSWIRE
Ipsen Expands Cabometyx Collaboration For Neuroendocrine Tumors
02 Jul 2024 //
GLOBENEWSWIRE
Exelixis Settles CABOMETYX Patent Litigation With Cipla
20 May 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
07 May 2024 //
BUSINESSWIRE
Exelixis Q1 2024 Results and Corporate Update
30 Apr 2024 //
BUSINESSWIRE
Exelixis To Release Q1 2024 Results On 4/30
16 Apr 2024 //
BUSINESSWIRE
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
27 Feb 2024 //
BUSINESSWIRE
